Log in with your email address username.


[Correspondence] The benefits of screening–and its harms

In response to our Viewpoint (Jan 16, pp 308–10) about screening for abdominal aortic aneurysms,1 Kosmas Paraskevas and colleagues (April 16, pp 1617–18)2 mention only the benefit (a diagnosis-specific mortality reduction) and ignore its harms. This is insufficient when one considers and compares screening programmes, which is indeed the central message of our Viewpoint.1 The research community commonly exhibit a strong focus on benefits of interventions, including screening, whereas important harms are not quantified—ie, in randomised trials.